High-Dose Diovan HCT To Launch In June
This article was originally published in The Pink Sheet Daily
Novartis plans to launch two higher-dose formulations of its hypertensive Diovan HCT (valsartan/hydrochlorothiazide) in early June
You may also be interested in...
The first ANDA with a Paragraph IV certification for Novartis' antihypertensive Diovan HCT (valsartan and hydrochlorothiazide) was filed Dec. 2, according to FDA's Feb. 6 updated list of filings
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.